by Crestone, Inc. | Dec 20, 2017 | Press Releases
Dec 20, 2017 – Announcement: Crestone enters a Research Agreement with Colorado University at Boulder to develop efflux pump modulators for the treatment of Gram-negative infections, thus adding a fourth program to its pipeline.
by Crestone, Inc. | Oct 30, 2017 | Events
Crestone presents two posters at Keystone Symposia (Santa Fe, NM). Optimization and Lead Selection of Benzothiazole-adamantyl Amide Analogs toward a Novel Antimycobacterial AgentPhase 1 Clinical Trial Results on the Safety and Pharmacokinetics of CRS3123, a Novel...
by Crestone, Inc. | Oct 18, 2017 | Events
Crestone presents an invited slide talk at Clinical & Pharmaceutical Microbiology, Rome, Italy: CRS3123, a Novel Narrow-Spectrum Agent in Clinical Development to Treat C. difficile Infections.
by Crestone, Inc. | Jun 3, 2017 | Events
Crestone presents Phase 1 data from single and multiple ascending dose clinical trials with CRS3123, at the ASM Microbe Meeting in New Orleans. CRS3123 is a drug candidate in development for the treatment of C. difficile infections. Learn More: Phase I Trial to...
by Crestone, Inc. | May 17, 2017 | Events
Crestone, Inc. presents at the NTMir Patient and Provider Conference in Dallas, TX. Poster: Optimization and Lead Selection of Benzothiazole Amide Analogs toward a Novel Antimycobacterial Agent
